These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 33276405)
41. Nusinersen for Patients With Spinal Muscular Atrophy: 1415 Doses via an Interdisciplinary Institutional Approach. Madan E; Carrié S; Donado C; Lobo K; Souris M; Laine R; Beers E; Cornelissen L; Darras BT; Koka A; Riley B; Dinakar P; Stone S; Snyder B; Graham RJ; Padua H; Sethna N; Berde C Pediatr Neurol; 2022 Jul; 132():33-40. PubMed ID: 35636280 [TBL] [Abstract][Full Text] [Related]
42. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067 [TBL] [Abstract][Full Text] [Related]
43. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy. Li Q Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169 [TBL] [Abstract][Full Text] [Related]
44. Ultrasound-guided interlaminar approach for nusinersen administration in patients with spinal muscular atrophy with spinal fusion or severe scoliosis. Wei C; Liang Z; Wu Y; Liu S; Qiu J; Meng L; Li C; Li S; Bao X; Wang Z; Chen L; Xiong H Orphanet J Rare Dis; 2023 Feb; 18(1):30. PubMed ID: 36800969 [TBL] [Abstract][Full Text] [Related]
45. Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study. Zhang J; Cui X; Chen S; Dai Y; Huang Y; Zhang S Orphanet J Rare Dis; 2021 Jun; 16(1):274. PubMed ID: 34120632 [TBL] [Abstract][Full Text] [Related]
46. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Gidaro T; Servais L Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755 [TBL] [Abstract][Full Text] [Related]
47. Successful Combination of Neuraxial and Regional Anesthesia in a Child With Advanced Spinal Muscular Atrophy Type 1 Receiving Maintenance Nusinersen Therapy: A Case Report. Brown AF; Einhorn LM A A Pract; 2020 Apr; 14(6):e01206. PubMed ID: 32784322 [TBL] [Abstract][Full Text] [Related]
49. Anesthetic management of pediatric patients undergoing intrathecal nusinersen administration for treatment of spinal muscular atrophy: A single-center experience. Brollier LD; Matuszczak M; Marri T; Carbajal JG; Moorman AT; Sorial EM; Jain R Paediatr Anaesth; 2021 Feb; 31(2):160-166. PubMed ID: 32623818 [TBL] [Abstract][Full Text] [Related]
50. A Systematic Review of Procedural Complications from Transforaminal Lumbar Puncture for Intrathecal Nusinersen Administration in Patients with Spinal Muscular Atrophy. Grayev A; Schoepp M; Kuner A AJNR Am J Neuroradiol; 2021 May; 42(5):980-985. PubMed ID: 33632735 [TBL] [Abstract][Full Text] [Related]
51. Intrathecal catheter and port placement for nusinersen infusion in children with spinal muscular atrophy and spinal fusion. Shashi KK; Stone SSD; Berde CB; Padua HM Pediatr Radiol; 2021 Dec; 51(13):2588-2595. PubMed ID: 34254153 [TBL] [Abstract][Full Text] [Related]
52. Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis. Rosiak G; Lusakowska A; Milczarek K; Konecki D; Fraczek A; Rowinski O; Kostera-Pruszczyk A Neuroradiology; 2021 Apr; 63(4):539-545. PubMed ID: 33512541 [TBL] [Abstract][Full Text] [Related]
53. Children and young adults with spinal muscular atrophy treated with nusinersen. Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321 [TBL] [Abstract][Full Text] [Related]
54. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511 [TBL] [Abstract][Full Text] [Related]
56. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy. Pacione M; Siskind CE; Day JW; Tabor HK J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933 [TBL] [Abstract][Full Text] [Related]
57. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland. Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602 [TBL] [Abstract][Full Text] [Related]
58. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience. Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971 [TBL] [Abstract][Full Text] [Related]
59. Nusinersen: A Review in 5q Spinal Muscular Atrophy. Hoy SM CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400 [TBL] [Abstract][Full Text] [Related]